Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
暂无分享,去创建一个
[1] M. Humbert,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2022, European Respiratory Journal.
[2] A. Beaudet,et al. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis , 2022, Journal of health economics and outcomes research.
[3] M. Kataoka,et al. Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension , 2022, Respiratory medicine case reports.
[4] K. Patel,et al. PRO18 A Systematic Literature Review of the Economic Burden and Cost Drivers in Pulmonary Arterial Hypertension , 2021, Value in Health.
[5] A. Beaudet,et al. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review , 2020, Pulmonary circulation.
[6] J. McConnell,et al. Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis , 2020, Pulmonary circulation.
[7] B. Dean,et al. Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study , 2020, Drugs - Real World Outcomes.
[8] Z. Jing,et al. Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.
[9] N. Maniadakis,et al. Cost-Effectiveness Of Selexipag For The Treatment Of Pulmonary Arterial Hypertension (PAH) In Greece , 2017 .
[10] H. Farber,et al. Practical considerations for therapies targeting the prostacyclin pathway , 2016, European Respiratory Review.
[11] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[12] C. Xiong,et al. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. , 2014, Pulmonary pharmacology & therapeutics.
[13] M. Humbert,et al. Targeted therapies in pulmonary arterial hypertension. , 2014, Pharmacology & therapeutics.
[14] M. Humbert,et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer , 2013, European Respiratory Review.
[15] Lane F Burgette,et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models , 2013, Statistics in medicine.
[16] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[17] Horst Olschewski,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.
[18] Laura A. Levit,et al. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. Washington, DC: National Academies Press , 2009 .
[19] Rivka L. Shoulson,et al. Bloodstream Infections in Patients Given Treatment With Intravenous Prostanoids , 2008, Infection Control & Hospital Epidemiology.
[20] R. Tuder,et al. Pathology of pulmonary hypertension. , 2007, Clinics in chest medicine.
[21] Simon Gibbs,et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.
[22] G. Raskob,et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. , 2011, Chest.
[23] M. Gladwin,et al. Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.